MDxHealth (MDXH) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• MDxHealth is scheduled to report Q1 2026 results on May 13, with analysts expecting EPS of ($0.1447) and revenue of $30.892 million.
• In the prior quarter the company missed EPS (reported ($0.17) vs. consensus ($0.13)) but beat revenue ($29.55M vs. consensus $26.05M), and it reported a negative net margin (31.07%) and a severely negative return on equity (1,078.01%).
• Shares trade near $2.02 with a market cap around $100M and a one‑year range of $1.69–$5.33; analysts’ consensus is a "Moderate Buy" with an average target of $7.75, though Weiss Ratings recently reissued a sell (D-) rating.

MDxHealth (NASDAQ:MDXH - Get Free Report) is projected to issue its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.1447) per share and revenue of $30.8920 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its quarterly earnings results on Friday, February 27th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.04). MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The firm had revenue of $29.55 million during the quarter, compared to the consensus estimate of $26.05 million. On average, analysts expect MDxHealth to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MDxHealth Price Performance

Shares of NASDAQ:MDXH opened at $2.02 on Thursday. The firm has a fifty day moving average price of $2.67 and a two-hundred day moving average price of $3.35. MDxHealth has a one year low of $1.69 and a one year high of $5.33. The company has a market cap of $99.98 million, a price-to-earnings ratio of -3.01 and a beta of 1.60.

Institutional Trading of MDxHealth

Hedge funds have recently made changes to their positions in the stock. Intesa Sanpaolo Wealth Management bought a new stake in shares of MDxHealth during the 4th quarter worth $36,000. Lido Advisors LLC bought a new stake in shares of MDxHealth during the 3rd quarter worth $48,000. Squarepoint Ops LLC bought a new stake in shares of MDxHealth during the 4th quarter worth $51,000. Jefferies Financial Group Inc. bought a new stake in shares of MDxHealth during the 3rd quarter worth $53,000. Finally, Balyasny Asset Management L.P. bought a new stake in shares of MDxHealth during the 4th quarter worth $68,000.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of MDxHealth in a report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $7.75.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth's lead product portfolio includes ConfirmMDx and SelectMDx.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.